News

2 Top Dividend Stocks to Buy on the Dip

Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in ...

Pfizer: This Is What Bulls Waited For

Pfizer beats Q2 estimates with $14.7B revenue and $0.78 EPS. Management showed extreme confidence by raising full-year EPS guidance. See more on PFE stock here.

Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease

Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned.

Pfizer Inc. (PFE) Comes Up With A Good Thing But No One Cares, Laments Jim Cramer

We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Pfizer Inc. (NYSE:PFE) is one of the ...
TipRanks on MSN21h

Pfizer’s (PFE) Sickle Cell Drug Fails to Meet Its Main Goal

Drugmaker Pfizer ($PFE) recently shared disappointing news about its experimental drug for sickle cell disease, inclacumab. In a late-stage ...
PharmExec21h

Pfizer’s Sickle Cell Treatment Fails Phase 3 Study

Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...

S&P 500: Profit Margins Cannot Hold

Discover how tariff policies and extreme valuations are impacting S&P 500 sectors. Click for my strategy and analysis of ...